W
Wellmarker Bio
Innovative drug discovery and development solutions leveraging AI for oncology and rare diseases
About Wellmarker Bio
Wellmarker Bio Co., Ltd. (wmbio.co) is a biotechnology startup that operates in the healthcare sector, specifically in the field of oncology. The company's primary focus is on the development of predictive biomarkers, which are biological indicators used to predict the effectiveness of cancer treatments before they are administered to patients. This approach is aimed at addressing unmet medical needs and improving the success rate of new drug development, while simultaneously reducing the time and cost associated with it.
The company's business model revolves around the research, development, and commercialization of these predictive biomarkers. By partnering with medical institutions like the Seoul Asan Hospital, Wellmarker Bio's team of researchers are able to leverage clinical information to aid in their development process. This collaboration allows them to create innovative, first-in-class cancer drugs based on their predictive biomarker technology.
Wellmarker Bio's primary customers are healthcare providers and institutions that deal with cancer treatment. By offering a method to predict treatment responses, the company provides a valuable tool that can help doctors make more informed decisions about patient care. This, in turn, can lead to better patient outcomes and potentially save lives.
The company generates revenue through the sale of its predictive biomarker-based cancer drugs. As these drugs are first-in-class, they have the potential to command premium pricing in the market due to their innovative nature and the significant value they provide in improving cancer treatment.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Seoul, South Korea
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 25.1/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Aug 2021 | — | — | Undisclosed | — |
| SERIES B✓Equity / VC | Oct 2020 | — | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Wellmarker Bio is 2.9K monthly website visits, up 81.3% over the last three months. Wellmarker Bio's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors3 additional known investors
HB Investment
Krypton
Muirwoods Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Wellmarker Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Wellmarker Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.